	US 12,247,982 B2
	Markers selectively deregulated in tumor-infiltrating regulatory T cells
Sergio Abrignani, Rapolano Terme (IT); and Massimiliano Pagani, Trescore Balneario (IT)
Assigned to CheckMab S.R.L., Milan (IT)
Filed by CheckMab S.R.L., Milan (IT)
Filed on Apr. 5, 2023, as Appl. No. 18/295,965.
Application 18/295,965 is a continuation of application No. 16/301,805, abandoned, previously published as PCT/EP2017/061642, filed on May 15, 2017.
Claims priority of application No. 16169791 (EP), filed on May 16, 2016; and application No. 16198724 (EP), filed on Nov. 14, 2016.
Prior Publication US 2023/0375555 A1, Nov. 23, 2023
Int. Cl. G01N 33/574 (2006.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01); C07K 14/47 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 15/113 (2010.01)

CPC G01N 33/57492 (2013.01) [A61K 35/17 (2013.01); A61K 45/06 (2013.01); C07K 14/4748 (2013.01); C07K 16/2866 (2013.01); C07K 16/30 (2013.01); C12N 5/0637 (2013.01); C12N 15/1135 (2013.01); C12N 15/1138 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01)]

1 Claim

1. A method for identifying an antibody acting as an anti-tumoral agent that depletes tumor-infiltrating regulatory T cells, comprising the steps of:

a) assaying candidate antibodies for their binding specificity to LAYN;

b) selecting antibodies having a specific binding activity to LAYN; and

c) testing the binding antibodies in a cell system comprising tumor-infiltrating regulatory T cells for their ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) on the tumor-infiltrating regulatory T cells, thereby identifying an antibody that depletes tumor-infiltrating regulatory T cells.